BLAINJECTIONINJECTABLE
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
3/8 — Basic
UNLOXCYT (cosibelimab) by Checkpoint Surgical is programmed death ligand-1 antagonists [moa]. First approved in 2024.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UNLOXCYT (cosibelimab) is a PD-L1 antagonist monoclonal antibody administered by injection that blocks programmed death ligand-1 to enhance anti-tumor immune responses. It represents a new entrant in the immuno-oncology space targeting cancer patients whose tumors express PD-L1. The drug was approved in December 2024 by Checkpoint Surgical.
Growth
Early-stage growth asset with limited current market penetration; commercial team expansion likely as launch matures and market share develops.
Mechanism of Action
Programmed Death Ligand-1 Antagonists
Pharmacologic Class:
Programmed Death Ligand-1 Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Started Apr 2026
80 enrolled
Cutaneous Squamous Cell CarcinomaSkin Cancer
Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC
Started Dec 2021
25 enrolled
Metastatic Non-squamous Non Small Cell Lung Cancer
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
Started Apr 2019
18 enrolled
B-cell Non Hodgkin LymphomaRichter's Transformation
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Started Sep 2017
272 enrolled
Lung NeoplasmsCarcinoma, Non-Small-Cell LungCarcinoma, Small Cell+10 more
Worked on UNLOXCYT at Checkpoint Surgical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.